A prospective study of 149 human immunodeficiency virus type 1 (HIV-1) seroconverters was conducted to describe trends and correlates of HIV-1 load after seroconversion and over time. HIV-1 load was quantified from frozen sera by reverse transcriptase-polymerase chain reaction. High early virus load was associated with lower CD4 cell counts and male sex but not with age at seroconversion or injection drug use. Early virus load predicted progression to clinical AIDS and AIDS/!200 CD4 cells/mL. Virus load exhibited a decline of 52% by 18 months after seroconversion then increased 23% annually (95% confidence interval, 13%-33%). Men and those developing AIDS during follow-up had higher virus loads over the course of disease. Persons who developed AIDS had a steeper virus load slope than those who were AIDS-free ( ). In long-term follow-up, virus load exhibited a gradual and sustained P = .01 increase over time. Virus load and annual increase are strong predictors of disease progression.
Plasma human immunodeficiency virus (HIV) type 1 RNA quantitation in conjunction with CD4 cell count has been an important prognostic indicator for the development of AIDS and death in predominantly seroprevalent cohorts of homosexual men and more recently in injection drug users (IDUs) [1, 2] . The prognostic value of plasma virus load has also been recognized soon after HIV seroconversion [3] [4] [5] [6] [7] .
It is generally understood that immediately after infection, plasma HIV load undergoes an initial peak in viral replication followed by a rapid drop to a steady-state level [5, [8] [9] [10] . It is unclear how long this virologic set point is maintained. Some prospective studies of serial determinations of virus load have shown stability of virus levels throughout the course of HIV infection [4, 11] . A few more recent studies noted a lack of longterm viral set point [5, 7, 12, 13] ; however, only two of these studies followed virus load from HIV seroconversion [5, 7] . The published studies showed differences in overall virus load levels between seroconverters who progressed rapidly to AIDS and those who remained asymptomatic [4, 5, 7, 12, 13] . Studies on longitudinal determinations of virus load starting at HIV seroconversion have been conducted on a small number of homosexual men only. Whether similar patterns are observed among other risk groups remains to be determined.
Although CD4 cell decline after HIV seroconversion differs by age, the relationship of HIV load and age soon after seroconversion and over time remains to be clarified. To address these questions, serial specimens obtained between 1987 and 1997 from HIV seroconverters from three centers participating in the Italian Seroconverter Study (ISS) were quantified for HIV load.
Methods
Study population. The study population is a subset of HIV seroconverters recruited into the ISS since 1987 and is currently followed with biannual visits for clinical and immunologic measures and morbidity and mortality outcomes. Details of this study have been described [14, 15] . In brief, the ISS is an open, multicenter cohort study (16 centers throughout Italy) that recruits identified seroconverters in different exposure categories, including IDUs, homosexual men, and heterosexual contacts. Three ISS centers (centers 2, 7, and 17) participated in this longitudinal virus load substudy.
Before 30 June 1997, 527 HIV seroconverters were identified within the three centers. Only the 508 persons with an HIV seroconversion window р2 years were eligible for this study. Of those 508, 149 had available frozen specimens for HIV load quantification and thus were included in this study. To assess correlates of early virus load and the predictability of early virus load on disease progression, we restricted our sample to participants with a virus load measure within the first 2 years after seroconversion. To assess longitudinal virus load patterns over the course of HIV disease, we included all 149 participants with у1 virus load measure through 30 June 1997.
Data collection. At each biannual clinic visit, participants provided medical history and physical examinations were done. Blood was collected for HIV serology and T cell subset studies and stored for future studies. Medical records were obtained and abstracted for clinical diagnoses. Data are routinely matched with the Italian National AIDS Registry to ascertain AIDS diagnoses, defined by the 1993 European AIDS definition, and with the bureau of viral statistics to ascertain date and cause of death.
Laboratory assays. Antibodies to HIV type 1 (HIV-1) were measured by commercial ELISA kit, and repeatedly positive specimens were confirmed by Western blot. T cell subsets were measured by flow cytometry by a whole blood staining method; absolute counts were determined using an automated complete blood count and differential. These measurements were made at each site with quality control protocol in place to ensure standardization across sites.
Serum HIV-1 RNA levels were quantified by using the reverse transcriptase-polymerase chain reaction (RT-PCR) Amplicor HIV-1 Monitor assay (Roche Molecular Systems, Branchburg, NJ) for all available visits to 30 June 1997 by all seroconverters from the three centers participating in this virus load substudy. RNA was extracted from heparinized samples and quantified according to the manufactor's instructions (dynamic range, ∼4 log; minimum detection limit, 400 copies/mL). Serum specimens were processed and stored at Ϫ70ЊC until testing. All HIV load testing was done at a single site.
Statistical analysis. The early virus load sample (within the first 2 years after seroconversion) was used to evaluate correlates of initial virus load and the predictability of initial virus load for HIV disease progression. The initial CD4 cell count was considered if obtained within 2 months of the initial virus load measure; this was available for all but 9 subjects. Medians of initial HIV load, CD4 cell counts, and age at estimated seroconversion date were reported overall and by risk factor by use of the Wilcoxon rank sum or Kruskal-Wallis tests for evaluating group differences. Multiple linear regression analysis was performed on the log 10 transformation of HIV load data to test for independent associations with initial virus load while simultaneously adjusting for several risk factors. A backward stepwise selection procedure was implemented after including covariates of interest from the univariate analyses in a full model, with a stopping criteria of . P ! .10 Also from the early virus load sample, we performed standard survival analysis to evaluate the predictability of initial HIV load on HIV disease progression. Two end points for disease progression were considered: the first clinical AIDS diagnosis (European 1993 AIDS definition) and the first of either clinical AIDS diagnosis or !200 CD4 cells/mL. Survival times were calculated as time from seroconversion date (estimated as the midpoint between the last negative date and the first positive date) to the first occurrence of either the event of interest, death, or the cutoff date of 30 June 1997. Cox proportional hazards regression models were fitted separately for each of the two end points to obtain relative hazard (RH) estimates and 95% confidence intervals (CIs) for variables of interest. Statistical significance was determined by the Wald test. The covariates included were initial HIV load, initial CD4 cell count, age at seroconversion, and initial HIV therapy use (prior to or at initial virus load, yes vs. no). Time (in years) from seroconversion to initial virus load was also considered because of the variation in the time lag. All covariates but initial HIV therapy use were treated as continuous variables.
All 149 participants were included to evaluate the trajectory of virus load and correlates of virus load over time. Mixed effects regression models were applied to account for dependencies among the repeated virus load measurements within a subject using a random regression line approach (or a random coefficients model) and an unstructured covariance matrix [16] . To evaluate the pattern in the population mean of the log 10 virus load, we assessed both a linear trend in time and a piecewise linear trend in time, with a change point 9-30 months after seroconversion. For simplicity, only 9, 12, 18, 24, and 30 months after seroconversion were considered as the possible change points in the piecewise linear regression model. The various models were compared via log-likelihood values and Akaike's information criterion. As a result, the piecewise linear model with a change point at 18 months was found to provide the best fit to the data and will be presented as the model of choice (data not shown).
Correlates of virus load over time were evaluated using a mixed effects linear model after adjusting for a temporal trend in virus load with a change in slope at 18 months after seroconversion. The final risk factor models were obtained via a forward stepwise approach.
Results
A comparison between the 149 subjects included in this study and the 359 persons excluded because of unavailable serum for virus load quantification showed no differences with respect to sex ( ), injection drug use ( ), age at serocon-P = .837 P = .617 version ( ), initial CD4 cell count ( ), and AIDS P = .586 P = .966 status by 30 June 1997 ( ). P = .104 Of the 149 study participants, 86 had a virus load measure within the first 2 years of their estimated seroconversion date and thus were included in the early virus load sample. Table 1 compares this subsample with the entire sample of 149 participants. The entire sample was 66% male and 60% IDUs, and study participants had a median age at seroconversion of 26 years, a median initial CD4 cell count of 485 cells/mL, and a median initial HIV load of 4861 copies/mL. Roughly 25% of the subjects developed AIDS, and 60% reported HIV therapy use at some point during follow-up. Participants reported HIV therapy use at 35% of visits, primarily monotherapy (82% of visits, mainly zidovudine) and combination nucleoside analogues (18% of therapy visits). No protease inhibitor use was reported.
In comparison, the early sample was of roughly the same age and risk group composition but had slightly more women than the entire sample (table 1). The early sample was composed of participants with higher median CD4 cells (619 cells/mL) and virus load (8318 copies/mL) than the entire sample but had similar cumulative rates of AIDS (23%) and HIV therapy use (62%). On the basis of the initial CD4 cell count alone, the early sample appeared to be slightly healthier than the entire sample of seroconverters.
Early sample: correlates of HIV load soon after seroconversion. Table 2 shows median virus loads, CD4 cells, and age at seroconversion overall and by risk factor for the 86 participants with a virus load finding within 2 years of seroconversion. HIV load was lower among women, IDUs, younger seroconverters, and those remaining AIDS-free throughout follow-up but was not statistically significant in any case. Virus load also appeared to be higher within the first 6 months after seroconversion than at 6-24 months after seroconversion, although this was not significant. Virus loads were similar with regard to the length of the seroconversion window and HIV therapy use during follow-up. In contrast, IDUs, younger seroconverters, and those reporting no HIV therapy use during follow-up had significantly higher initial CD4 cell counts. In addition, women, IDUs, and those reporting no HIV therapy were significantly younger at seroconversion.
Because of the observed associations between CD4 cell count, age, sex, and injection drug use, we performed a multiple linear regression analysis to evaluate any differences in the log of virus load while controlling for the potential confounders. By using a backward stepwise approach for model selection, including the variables in table 2, the final model included effects for time after seroconversion, sex, and CD4 cell count (data not shown). In addition, we adjusted for center in the final model. The mean virus load was roughly 0.5 log greater (a 3-fold increase) in the first year after seroconversion than the second year ( ). P = .005 For every 100-cell drop in CD4 cells, the mean log virus load was associated with an increase of 0.05 ( ) or a 12% P = .035 increase in virus load. Women were estimated to have about a one-third log lower mean virus load than men ( ) or a P = .065 CD4 cells/mL (low CD4 cell count). The median time to event was 4.7 years for those developing clinical AIDS and 4.9 years for those considered to be free of AIDS. Similarly, the median time to event was 3.1 years for those who either developed clinical AIDS or had low CD4 cells and 4.2 years for those censored free of both events. As shown in table 3, a higher HIV load soon after seroconversion was independently predictive of faster disease progression as defined by either clinical AIDS ( , ) RH = 2.09 P = .042 or clinical AIDS or low CD4 cell count ( , ). RH = 1.80 P = .030 When we used the clinical AIDS or low CD4 cell count definition, older age at seroconversion ( , ) was RH = 1.66 P = .033 associated with faster disease progression. There was also a significant association between prior HIV therapy use and faster disease progression ( for AIDS; for AIDS/ P = .064 P = .006 low CD4 cell counts) despite fairly wide CIs. CD4 cell count soon after seroconversion was not independently associated with HIV disease progression (table 3) .
Longitudinal sample: trends in HIV load over time. To evaluate longitudinal trends in HIV load after seroconversion, we considered all 149 participants described in table 1. There were a total of 531 virus load measures, averaging 4 per subject (range, 1-12/subject). The virus load measures extended to 11.3 years after seroconversion (median, 3.5 years after seroconversion). The median (interquartile range) of HIV load over the follow-up period was 8069 copies/mL (range, 2263-28,800).
Allowing for a change in slope of virus load at 18 months after seroconversion, the virus load was estimated to decrease by 0.21 log 10 copies/mL per year during the first 18 months ( ) and thereafter to increase by 0.09 log 10 copies/mL P = .025 per year (  ; table 4 ). This corresponded to a 52% decline P ! .001 in copies per milliliter (95% CI, Ϫ74% to Ϫ10%) by 18 months after seroconversion, then a 23% annual increase in copies per milliliter (95% CI, 13%-33%) beyond 18 months after seroconversion. Figure 1 displays the estimated mean level of HIV load on the log 10 scale while allowing for a change in linear trend 18 months after seroconversion. The model-based estimates of virus load at 6 months and 2, 4, and 8 years after seroconversion were 3.85, 3.68, 3.86, and 4.22 log 10 copies/mL, respectively, suggesting a relatively stable level over 4 years. This piecewise linear model provided a significantly better fit to the data than a linear model (data not shown). Even when assuming a single linear slope over the entire follow-up period, the annual increase in virus load was estimated as 0.05 log 10 copies/mL per year ( ) or a 12% annual increase in cop-P = .002 ies per milliliter (95% CI, 5%-21%). When the follow-up was truncated to only 5 years after seroconversion, the increase after 18 months was only slightly dampened to a 22% annual increase in virus load ( ). However, the overall linear change in P = .006 virus load beginning at seroconversion was negligible (3% increase/year, ) when truncating to 5 years of follow-up. P = .613 This piecewise linear model was also compared with two other nonlinear models of the population mean of log 10 virus load: a quadratic model, which allowed for an increasing slope in virus load over time, and a "step function" model, which allowed the virus load level to be constant over the 6 time intervals (0-0.5, 0.5-1.5, 1.5-3.0, 3.0-5.0, 5.0-7.0, and 17.0 years after seroconversion). Neither regression model provided a better fit to the data than the piecewise linear model with a change point at 18 months after seroconversion (data not shown).
In the final model adjusting for the trend in time (table 4) , current CD4 cell count, AIDS diagnosis, and male sex were positively associated with mean level of log 10 HIV load. Subjects with р200 CD4 cells/mL had roughly an 85% increase in virus load compared with persons with 1200 CD4 cells/mL (P = ). Male participants had an estimated 1.9-fold higher virus .002 load than female participants ( ). Also, persons who P = .012 developed AIDS had about a 2-fold increase in virus load ( ). No other covariates were significant after controlling P = .020 for time trend, current CD4 cells, sex, and an AIDS diagnosis (data not shown), although age at seroconversion showed a borderline positive association with virus load ( ). P = .158 Within the final model accounting for a piecewise linear trend in virus load, we also assessed whether the change in virus load beyond the initial 18 months after seroconversion differed by injection drug use, age at seroconversion, sex, and AIDS status. Age was dichotomized as р30 versus 130 years, where 28% fell into the older category and injection drug use was split by injection drug use versus other risk group. No difference in virus load slope was detected by age ( ), sex ( ), P = .136 P = .956 or injection drug use ( ). Those who developed AIDS P = .392 during the follow-up, however, experienced a significantly faster increase in virus load (30% per year) 18 months after seroconversion than those remaining free of AIDS (5.4% per year;
). P = .013
Discussion
This study yields several major findings. First, HIV load is the strongest predictor for disease progression. In the crosssectional analysis, early levels of HIV load were inversely associated with CD4 cell count, which has been used as an intermediate or surrogate measure of HIV progression. These results are consistent with virtually every other cross-sectional study published to date.
In the study sample, defined by a virus load measurement soon after HIV seroconversion, virus load was the strongest predictor for the subsequent development of clinical AIDS (with or without !200 CD4 cells/mL). Although this result was observed in other seroincident cohorts [3] [4] [5] [6] [7] , our results represent a demographically more diverse group than those assessed earlier. Moreover, our results are consistent with data from seroprevalent cohort studies in predominantly white homosexual men [1] and in African-American IDUs [2] in that virus load measurements were the most important single predictor of HIV disease progression.
When the study sample defined by longitudinal virus load measurements was considered, overall virus load levels were significantly higher in persons who developed AIDS than in those who remained AIDS-free, consistent with more limited longitudinal data previously reported [4, 5, 7, 12, 13] . In addition, we observed a higher rate of increase in virus load over time among those who developed AIDS than in the AIDS-free participants. Combined, these three lines of evidence from our study underscore the importance of virus load measurements in predicting HIV disease progression.
Although virus load is an important predictor of HIV disease progression, the relationship is not simply linear. In the crosssectional analysis, which included single measurements within 24 months of seroconversion, the virus load was higher in those measured in the first 6 months than in those measured in the following 18 months after the estimated date of seroconversion. This result is consistent with earlier reports that virus load rises dramatically around the time of onset of infection but then drops within a year thereafter [5, [8] [9] [10] . Given the widely recognized inverse association of virus load and CD4 cell counts, these results are also entirely consistent with earlier reports of dramatic drops in CD4 cells around the time of onset of infection that then rise during the following year before subsequent longitudinal patterns are observed [17] .
Despite the general agreement in the literature on virus load patterns soon after the onset of HIV infection, longitudinal data on HIV load measurement patterns after this period are sparse [4, 5, 7, [11] [12] [13] . Some earlier reports suggested that after the dramatic rise and fall of virus load surrounding the onset of infection, a "set point" was achieved after which change in virus load appeared to be relatively modest [4, 11] . Our data showed a significant increase over time beyond the initial 18 months after seroconversion that corresponded to an estimated 23% increase in virus load per year. The piecewise linear model showed that the pattern was nonlinear because of the initial virus load decline in the 18 months after seroconversion. The subtle differences between the findings from early reports and our data probably reflect the fact that we analyzed a larger sample covering a longer time frame, thus greatly increasing our power of detection. Indeed, when our data are truncated at 5 years of follow-up after seroconversion and a single linear trend from seroconversion is sought, the increase in virus load becomes less apparent. Others with sufficient longitudinal data have also reported increased virus loads after seroconversion in homosexual men [5, 7] and among IDUs in Baltimore [18] .
Given the relationship of virus load and HIV disease progression, the role or effect of other covariates should be considered. Some researchers have noted that at the same CD4 cell count, virus load is lower among women than men [19, 20] . In our study, we noted that initial virus load was lower in women than men at similar CD4 cell levels. Our longitudinal virus load data also showed a significantly lower virus load in women than men but no difference in slope of virus load by sex. Additional studies with larger patient populations and longer follow-up will be needed to substantiate these findings.
Although early studies suggested that use of illicit drugs, particularly among IDUs, might result in a more rapid clinical deterioration because of immunosuppressive properties of some drugs or in vitro evidence for up-regulation of HIV itself, the bulk of the large-scale clinical epidemiologic findings to date have failed to identify differences in CD4 cell decline or rate of HIV disease progression by risk group [14, 15, 21] . In our study, which provides new information on virus load measurements in different risk groups, no significant differences in initial or long-term virus load were observed between IDUs and nonIDUs. These results in combination with the earlier studies suggest a similar natural history of HIV infection among these different risk groups. Although illicit drug use history continues to be important to consider for issues of adherence to therapy, there is little evidence to suggest that use of illicit drugs alters the biologic course of infection in a way that would require a different pharmacologic approach to treating the infection itself.
Before firm conclusions are drawn, several study limitations should be acknowledged. The participants selected for this analysis were enrolled from three centers that had serum specimens available for virus load measurements. The extent to which these persons are representative of others with HIV infection in Italy or elsewhere is unknown. Also, for this study, RT-PCR was done on frozen repository serum specimens. Other studies have noted systematic variability in virus load measurements by assay and specimen type (e.g., plasma vs. serum) and storage method (heparin vs. EDTA). Therefore, caution is required when interpreting absolute values of the virus load measurements in our report, although the relative difference that underlie the inferences remain valid. Finally, this study included HIV seroconverters followed up to 11 years. The extent to which inferences about associations with development of AIDS diagnoses are therefore limited to mostly rapid progressors and might not reflect the full range of the incubation period for AIDS needs to be highlighted. Future analyses with additional follow-up might help clarify this concern. However, the introduction of highly effective antiretroviral combination therapies, especially in Italy, which provides universal health care coverage, may limit our ability to resolve this concern in future data.
In conclusion, both early and later HIV load measurements are strong independent predictors for subsequent clinical outcomes. In addition, the rate of increase in virus load over the course of the disease is highly predictive of the development of AIDS. Our findings also show that the course of HIV load is marked by a slight fall shortly after infection, followed by a steady increase over time. The longitudinal trends appear to be relatively unaffected by demographic characteristics, suggesting that virus load represents an important tool for clinical management of HIV infection across different populations within developed countries.
